Merck & Co./$MRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Merck & Co.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Ticker
$MRK
Sector
Primary listing
NYSE
Employees
74,000
Headquarters
Website
Merck & Co. Metrics
BasicAdvanced
$203B
12.51
$6.49
0.39
$3.20
3.99%
Price and volume
Market cap
$203B
Beta
0.39
52-week high
$117.87
52-week low
$73.31
Average daily volume
11M
Dividend rate
$3.20
Financial strength
Current ratio
1.424
Quick ratio
0.82
Long term debt to equity
69.238
Total debt to equity
71.992
Dividend payout ratio (TTM)
48.95%
Interest coverage (TTM)
18.77%
Profitability
EBITDA (TTM)
29,157
Gross margin (TTM)
77.41%
Net profit margin (TTM)
25.79%
Operating margin (TTM)
37.64%
Effective tax rate (TTM)
14.32%
Revenue per employee (TTM)
$860,000
Management effectiveness
Return on assets (TTM)
13.01%
Return on equity (TTM)
35.42%
Valuation
Price to earnings (TTM)
12.512
Price to revenue (TTM)
3.215
Price to book
4.15
Price to tangible book (TTM)
18.74
Price to free cash flow (TTM)
13.905
Free cash flow yield (TTM)
7.19%
Free cash flow per share (TTM)
5.835
Dividend yield (TTM)
3.94%
Forward dividend yield
3.99%
Growth
Revenue change (TTM)
1.82%
Earnings per share change (TTM)
20.41%
3-year revenue growth (CAGR)
3.63%
10-year revenue growth (CAGR)
4.68%
3-year earnings per share growth (CAGR)
-0.21%
10-year earnings per share growth (CAGR)
6.60%
3-year dividend per share growth (CAGR)
5.65%
10-year dividend per share growth (CAGR)
5.91%
What the Analysts think about Merck & Co.
Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.
Bulls say / Bears say
Merck’s lead immuno-oncology drug, Keytruda, posted a 9% year-over-year sales increase to just under $8.0 billion in Q2 2025, thanks to expanded approvals for both early-stage and metastatic cancers (Reuters).
The U.S. FDA’s approval of Enflonsia (clesrovimab-cfor) for RSV prevention in infants marks Merck’s first RSV prophylactic effective regardless of weight, strengthening its pediatric vaccine lineup and providing a fresh growth driver for the 2025-2026 RSV season (Reuters).
Merck’s experimental oral PCSK9 inhibitor, enlicitide decanoate, achieved its main goals in two late-phase CORALreef studies by delivering meaningful LDL-C reductions, setting Merck up to enter the cholesterol management market as the first oral PCSK9 therapy (Reuters).
Merck’s Gardasil vaccine sales dropped 55% year-over-year to $1.1 billion in Q2 2025, mainly due to weak demand in China and a halt in shipments, signaling a major challenge for its vaccine division (Reuters).
Investors are worried about the looming loss of Keytruda’s patent protection in 2028, as Keytruda made up almost half of Merck’s 2024 revenue, and there’s uncertainty if new drugs in the pipeline can fully cover the expected decline (Reuters).
Even after cost reduction measures, Merck slightly lowered its 2025 full-year sales forecast to $64.3–$65.3 billion after a 2% drop in Q2 revenue, highlighting continued pressure on revenue growth and dependence on cutting costs (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Merck & Co. Financial Performance
Revenues and expenses
Merck & Co. Earnings Performance
Company profitability
Merck & Co. News
AllArticlesVideos
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025
Business Wire1 day ago
Oakmark Funds' Bill Nygren: Here's where to look beyond the Mag 7
CNBC Television2 days ago
Merck's pneumonia shot shows promise in late-stage study
Reuters1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Oct7
Merck & Co.
DividendPayment
$0.81Per share
FAQs
What’s the current market cap for Merck & Co. stock?
Merck & Co. (MRK) has a market cap of $203B as of September 18, 2025.
What is the P/E ratio for Merck & Co. stock?
The price to earnings (P/E) ratio for Merck & Co. (MRK) stock is 12.51 as of September 18, 2025.
Does Merck & Co. stock pay dividends?
Yes, the Merck & Co. (MRK) stock pays dividends to shareholders. As of September 18, 2025, the dividend rate is $3.2 and the yield is 3.99%. Merck & Co. has a payout ratio of 48.95% on a trailing twelve-month basis.
When is the next Merck & Co. dividend payment date?
The next Merck & Co. (MRK) dividend payment is scheduled for October 07, 2025.
What is the beta indicator for Merck & Co.?
Merck & Co. (MRK) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.